Gilead takes a hit af­ter a close­ly-watched Covid-19 tri­al of remde­sivir is qui­et­ly ter­mi­nat­ed, rais­ing fresh doubts

Shares of Gilead took a 3% hit $GILD Wednes­day af­ter re­searchers not­ed that they had sus­pend­ed one of the close­ly-watched Covid-19 stud­ies for remde­sivir in Chi­na.

Ini­tial­ly high­light­ed in a note from RBC Cap­i­tal, an up­date on clin­i­cal­tri­ to­day stat­ed that the Phase III for mild to mod­er­ate pa­tients had to be ter­mi­nat­ed due to a lack of pa­tients to en­roll. The spon­sor is Cap­i­tal Med­ical Uni­ver­si­ty with the Chi­nese Acad­e­my of Med­ical Sci­ences list­ed as a col­lab­o­ra­tor.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.